NCT03800693
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 15 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Aug 5, 2026 to Aug 5, 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 27 words
- Study completion pushed from Sep 17, 2026 to Sep 17, 2028
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised at 3 of 3 sites
- Collaborators: details revised at 1 of 2 entries
- Notable Primary completion date: Sep 17, 2025 to Aug 5, 2026v14
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary completion date: Dec 31, 2024 to Sep 17, 2025
- Study completion date: Dec 31, 2024 to Sep 17, 2026
- Site details revised at 3 of 3 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary and study completion dates: Nov 4, 2024 to Dec 31, 2024
- Site details revised at 3 of 3 sites
- Minor Site contacts updated at 3 of 3 sitesv11
Show 9 earlier versionsHide 9 earlier versions
- Notable Primary and study completion dates pushed to Nov 4, 2024v10
- Notable Primary completion date: Nov 4, 2022 to Nov 4, 2023
- Study completion date: Mar 31, 2023 to Mar 31, 2024
- Minor Site contacts updated at 1 of 3 sitesv8
- Notable Primary completion date: Mar 31, 2021 to Nov 4, 2022v7
- Minor Site contacts updated at 3 of 3 sitesv6
- Notable Eligibility criteria expanded, about 2 wordsv5
- Notable Eligibility criteria expanded, about 30 words
- Site contacts updated at 2 of 3 sites
- Minor Study sites: 1 to 3v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Primary completion date: Jan 31, 2022 to Mar 31, 2021
- Study completion date: Jan 31, 2024 to Mar 31, 2023
- Start date changed from estimate of Jan 1, 2020 to Mar 14, 2019
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Drugs: Fluorouracil, Leucovorin, Oxaliplatin
Sites
3 sites in 1 country